Morgan Stanley Raises Insulet (NASDAQ:PODD) Price Target to $317.00

Insulet (NASDAQ:PODD) had its target price increased by Morgan Stanley from $234.00 to $317.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

A number of other research firms also recently weighed in on PODD. Sanford C. Bernstein began coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Barclays raised their target price on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Piper Sandler lifted their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Stock Performance

Shares of Insulet stock opened at $269.06 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market cap of $18.87 billion, a price-to-earnings ratio of 46.07, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. The stock’s 50-day moving average is $235.96 and its 200-day moving average is $206.47. Insulet has a one year low of $160.19 and a one year high of $279.40.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet during the second quarter worth approximately $32,000. Venturi Wealth Management LLC lifted its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. UMB Bank n.a. boosted its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the period. Finally, CVA Family Office LLC grew its holdings in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.